JP2023506779A5 - - Google Patents
Info
- Publication number
- JP2023506779A5 JP2023506779A5 JP2022535607A JP2022535607A JP2023506779A5 JP 2023506779 A5 JP2023506779 A5 JP 2023506779A5 JP 2022535607 A JP2022535607 A JP 2022535607A JP 2022535607 A JP2022535607 A JP 2022535607A JP 2023506779 A5 JP2023506779 A5 JP 2023506779A5
- Authority
- JP
- Japan
- Prior art keywords
- csf
- pharmaceutical composition
- antibody
- composition according
- versus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945842P | 2019-12-09 | 2019-12-09 | |
| US62/945,842 | 2019-12-09 | ||
| US202063110111P | 2020-11-05 | 2020-11-05 | |
| US63/110,111 | 2020-11-05 | ||
| PCT/US2020/064010 WO2021119128A1 (en) | 2019-12-09 | 2020-12-09 | Antibodies for the treatment of chronic graft versus host disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023506779A JP2023506779A (ja) | 2023-02-20 |
| JP2023506779A5 true JP2023506779A5 (enExample) | 2023-12-13 |
Family
ID=76330540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535607A Pending JP2023506779A (ja) | 2019-12-09 | 2020-12-09 | 慢性移植片対宿主病の処置用抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12552869B2 (enExample) |
| EP (1) | EP4073100A4 (enExample) |
| JP (1) | JP2023506779A (enExample) |
| KR (1) | KR20220123004A (enExample) |
| CN (3) | CN115298210A (enExample) |
| AU (1) | AU2020401551A1 (enExample) |
| CA (1) | CA3164126A1 (enExample) |
| IL (1) | IL293705A (enExample) |
| MX (1) | MX2022007029A (enExample) |
| PH (1) | PH12022551401A1 (enExample) |
| WO (1) | WO2021119128A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN121219009A (zh) * | 2023-05-17 | 2025-12-26 | 信达克思制药公司 | 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病相关的闭塞性细支气管炎综合征的方法 |
| AU2024300057A1 (en) * | 2023-07-23 | 2026-01-08 | Incyte Corporation | Methods of treating chronic graft-versus-host disease using an anti-colony stimulating factor 1 receptor antibody |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| WO2005014655A2 (en) | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| CN102218070A (zh) * | 2004-12-30 | 2011-10-19 | 索利吉尼克斯公司 | 用二丙酸倍氯米松和泼尼松治疗移植物抗宿主病和白血病 |
| KR20080074120A (ko) | 2005-10-13 | 2008-08-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물 |
| JP2010500283A (ja) | 2006-05-31 | 2010-01-07 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法 |
| US20080114007A1 (en) | 2006-10-31 | 2008-05-15 | Player Mark R | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase |
| JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトｃ−ｆｍｓ抗原結合性タンパク質 |
| JO3240B1 (ar) | 2007-10-17 | 2018-03-08 | Janssen Pharmaceutica Nv | c-fms مثبطات كيناز |
| TW200944231A (en) | 2007-11-30 | 2009-11-01 | Glaxo Group Ltd | Antigen-binding constructs |
| US8470977B2 (en) | 2008-03-14 | 2013-06-25 | Transgene S.A. | Antibody against the CSF-1R |
| RU2547586C2 (ru) | 2008-03-14 | 2015-04-10 | Трансжене С.А. | Антитело против csf-1r |
| US8492357B2 (en) | 2008-08-01 | 2013-07-23 | Santaris Pharma A/S | Micro-RNA mediated modulation of colony stimulating factors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| AR080698A1 (es) | 2010-04-01 | 2012-05-02 | Imclone Llc | Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| UY33801A (es) | 2010-12-13 | 2013-06-28 | Array Biopharma Inc | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III |
| KR102061358B1 (ko) | 2011-10-21 | 2019-12-31 | 트랜스진 에스.에이. | 대식세포 활성화의 조절 |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| GB201315486D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| SG11201705484WA (en) | 2015-02-09 | 2017-08-30 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| US12168054B2 (en) * | 2017-05-19 | 2024-12-17 | Syndax Pharmaceuticals, Inc. | Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody |
-
2020
- 2020-12-09 PH PH1/2022/551401A patent/PH12022551401A1/en unknown
- 2020-12-09 EP EP20899869.0A patent/EP4073100A4/en active Pending
- 2020-12-09 CN CN202080095646.6A patent/CN115298210A/zh active Pending
- 2020-12-09 KR KR1020227023446A patent/KR20220123004A/ko active Pending
- 2020-12-09 JP JP2022535607A patent/JP2023506779A/ja active Pending
- 2020-12-09 CN CN202610407661.9A patent/CN122399012A/zh active Pending
- 2020-12-09 MX MX2022007029A patent/MX2022007029A/es unknown
- 2020-12-09 CN CN202610407659.1A patent/CN122461447A/zh active Pending
- 2020-12-09 IL IL293705A patent/IL293705A/en unknown
- 2020-12-09 WO PCT/US2020/064010 patent/WO2021119128A1/en not_active Ceased
- 2020-12-09 CA CA3164126A patent/CA3164126A1/en active Pending
- 2020-12-09 AU AU2020401551A patent/AU2020401551A1/en active Pending
- 2020-12-09 US US17/783,552 patent/US12552869B2/en active Active
-
2026
- 2026-01-13 US US19/447,470 patent/US20260132210A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025016606A5 (enExample) | ||
| JP2019523295A5 (enExample) | ||
| JP2010520290A5 (enExample) | ||
| JP2011506483A5 (enExample) | ||
| US20240368262A1 (en) | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders | |
| JP2020525411A5 (enExample) | ||
| CA2984464C (en) | Treatment for multiple myeloma (mm) | |
| CN110799543A (zh) | 肝细胞癌的免疫治疗 | |
| IL319803A (en) | Methods and compositions for treating amyloid deposition diseases | |
| JP2018522540A5 (enExample) | ||
| JP2024534602A5 (enExample) | ||
| JP2022536088A5 (enExample) | ||
| JP2025514978A5 (enExample) | ||
| JP2013521252A5 (enExample) | ||
| WO2013140787A1 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| JP2024540435A5 (enExample) | ||
| JP2024540226A5 (enExample) | ||
| JP2022542472A5 (enExample) | ||
| JP2021529766A5 (enExample) | ||
| JP2021523138A5 (enExample) | ||
| JP2023537078A5 (enExample) | ||
| CN114729054A (zh) | 使用免疫检查点抑制剂抗体治疗癌症的方法和组合 | |
| JP2022512346A5 (enExample) | ||
| JP2024528877A5 (enExample) | ||
| JP7093940B2 (ja) | 全身性強皮症治療用医薬組成物 |